Therefore, specific FGF12-targeted therapies, including selective FGFR inhibitors and neutralizing antibodies, could potentially be developed to inhibit FGF-mediated cell proliferation across all ESS subtypes. This evidence concerns the gene FGF12 and endometrioid stromal sarcoma.